MB
TVTX icon

MPM BioImpact’s Travere Therapeutics TVTX Stock Holding History

MPM BioImpact’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.7M Buy
+1,133,365
New +$33.9M 2.6% 14
2023
Q4 		– Sell
-552,846
Closed -$4.94M – 34
2023
Q3 		$4.94M Hold
552,846
– – 1.32% 25
2023
Q2 		$8.49M Buy
552,846
+239,204
+76% +$4.35M 1.71% 19
2023
Q1 		$7.05M Buy
313,642
+31,931
+11% +$679K 1.83% 15
2022
Q4 		$5.92M Buy
281,711
+5,251
+2% +$111K 1.54% 18
2022
Q3 		$6.81M Sell
276,460
-1,490
-0.5% -$38.5K 1.61% 17
2022
Q2 		$6.74M Hold
277,950
– – 1.87% 14
2022
Q1 		$7.16M Sell
277,950
-9,943
-3% -$264K 1.92% 14
2021
Q4 		$8.94M Sell
287,893
-18,622
-6% -$524K 1.63% 16
2021
Q3 		$7.43M Buy
+306,515
New +$5.63M 1.15% 20

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return